Danaher Q4 earnings exceed expectations, with a core revenue growth target of 3%-6% by 2026

According to a report by the Economic Observer on February 12, 2026, Danaher (DHR.N) has been a major focus over the past week (February 6 to 12, 2026), including plans to release its official financial results for Q4 and the full year in late February 2026. Management pre-disclosed better-than-expected Q4 performance at the JPMorgan Healthcare Conference (JPM2026) on January 13, 2026. Additionally, the company outlined core revenue growth targets of 3% to 6% for fiscal year 2026. Recently, Danaher has taken strategic actions such as entering e-commerce platforms to expand online sales and collaborating with Meigu Molecular and Changfa to invest in organoid technology, strengthening its presence in the life sciences sector.

Financial Report Analysis

Danaher’s Q4 2025 performance was strong: revenue reached $6.838 billion, up 4.5% year-over-year (core growth of 2.5%), with adjusted earnings per share (EPS) of $2.23, up 4%. The biotech segment grew by 8.8% year-over-year, while life sciences and diagnostics segments increased by 2.6% and 3.1%, respectively. Management stated at JPM2026 that growth in 2026 will depend on the recovery of the life sciences market and the rebound of the Chinese diagnostics market, providing guidance of 3% to 6% core revenue growth and an expansion of operating profit margin by over 100 basis points.

Recent Stock Performance

As of the close on February 12, 2026, Danaher’s stock price was $215.27, down 2.14% for the day, with a low of $208.55 (a 5.02% intraday range). Over the past five days, the stock declined by 0.22%, with a total fluctuation of 5.68%. The trading volume was $690.1 million, with a turnover rate of 0.46%. During the same period, the U.S. life sciences sector fell by 2.59%, and the Nasdaq index declined by 1.56%, indicating that individual stocks were affected by sector and market trends.

Institutional Opinions

Institutions maintain a positive outlook on Danaher: as of February 2026, 89% of 28 institutions rated the stock as “Buy” or “Overweight,” with an average target price of $264.18 (highest $310). Citigroup and other firms highlighted the company’s disciplined M&A approach and the potential for market recovery but did not adjust short-term ratings. Regarding earnings forecasts, 22 institutions expect Q4 2025 EPS of $2.23, with a 7.69% year-over-year revenue increase in Q1 2026.

The above information is compiled from public sources and does not constitute investment advice.